SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by AspenBio Pharma, Inc. on April 1, 2008, reporting events that occurred on March 27, 2008. The filing addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director. Note: The request metadata referenced "Riot Platforms, Inc."; however, the provided source text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors amended the Company's Bylaws to expand the maximum number of directors to nine.
- New Appointment: Mark J. Ratain, M.D., was appointed to the Board to fill a vacancy created by the expansion. He serves until the 2008 Annual Meeting of Shareholders or until a successor is elected.
- Director Compensation: Dr. Ratain received an initial grant of stock options for 66,313 common shares at an exercise price of $6.13 per share. These options vest annually in arrears over three years and expire in ten years. Additionally, he will receive cash compensation of $1,000 per month as an independent director.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, management commentary on operations, or specific risk factors. The primary disclosure relates to the qualifications of the new director, Dr. Ratain, who is a hematologist/oncologist and clinical pharmacologist with extensive experience at the University of Chicago and DATATRAK International, Inc.
Key Facts for Investor Verification
- Verify the total number of directors on the Board following the expansion to nine members.
- Confirm the vesting schedule and expiration date of the 66,313 stock options granted to Dr. Ratain.
- Review the attached press release (Exhibit 99.1) for additional context on the strategic rationale for the appointment.
- Check subsequent filings for the outcome of the 2008 Annual Meeting of Shareholders regarding Dr. Ratain's election.